Author Affiliations: The Center for Civilian Biodefense Strategies (Drs Inglesby, O'Toole, Henderson, Bartlett, and Perl) and the Schools of Medicine (Drs Inglesby, Bartlett, and Perl) and Public Health (Drs O'Toole and Henderson), Johns Hopkins University, Department of Health and Human Services (Drs Ascher, and Russell and Mr Hauer), Baltimore, and US Army Medical Research Institute of Infectious Diseases, (Drs Eitzen, Friedlander, and Parker), Frederick, Md; Centers for Disease Control and Prevention, Atlanta, Ga (Drs Hughes, McDade, and Gerberding); Center for Infectious Disease Research and Policy, University of Minnesota School of Public Health, Minneapolis (Dr Osterholm); and the Office of Emergency Preparedness, Department of Health and Human Services, Rockville, Md (Dr Tonat).
Objective To review and update consensus-based recommendations for medical and
public health professionals following a Bacillus anthracis attack against a civilian population.
Participants The working group included 23 experts from academic medical centers,
research organizations, and governmental, military, public health, and emergency
management institutions and agencies.
Evidence MEDLINE databases were searched from January 1966 to January 2002, using
the Medical Subject Headings anthrax, Bacillus anthracis, biological weapon, biological terrorism, biological warfare, and biowarfare. Reference review identified
work published before 1966. Participants identified unpublished sources.
Consensus Process The first draft synthesized the gathered information. Written comments
were incorporated into subsequent drafts. The final statement incorporated
all relevant evidence from the search along with consensus recommendations.
Conclusions Specific recommendations include diagnosis of anthrax infection, indications
for vaccination, therapy, postexposure prophylaxis, decontamination of the
environment, and suggested research. This revised consensus statement presents
new information based on the analysis of the anthrax attacks of 2001, including
developments in the investigation of the anthrax attacks of 2001; important
symptoms, signs, and laboratory studies; new diagnostic clues that may help
future recognition of this disease; current anthrax vaccine information; updated
antibiotic therapeutic considerations; and judgments about environmental surveillance
Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Gerberding J, Hauer J, Hughes J, McDade J, Osterholm MT, Parker G, Perl TM, Russell PK, Tonat K, for the Working Group on Civilian Biodefense . Anthrax as a Biological Weapon, 2002Updated Recommendations for Management. JAMA. 2002;287(17):2236-2252. doi:10.1001/jama.287.17.2236